论文部分内容阅读
非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明确的损肝因素所致,以弥漫性肝细胞大泡性脂肪变为主要特征的临床病理综合征,包括单纯性脂肪肝以及由其演变的脂肪性肝炎和肝硬化,胰岛素抵抗和遗传易感性与其发病关系密切。目前关于非酒精性脂肪性肝病的治疗主要以饮食控制及运动减重为主,对于血脂紊乱经基础治疗和(或)应用减肥降糖药物1个月以上,仍呈混合性高脂血症或高脂血症合并2个以上危险因素者,需考虑加用贝特类、他汀类或普罗布考等降血脂药物。本文就降脂药在NAFLD防治中的应用做一综述。
Non-alcoholic fatty liver disease (NAFLD) refers to the clinical pathological syndrome characterized by diffuse hepatocytic bullous steatosis, except for alcohol and other definite liver damage factors, including simple fatty liver and its Evolved steatohepatitis and cirrhosis, insulin resistance and genetic predisposition and its incidence are closely related. The current treatment of non-alcoholic fatty liver disease mainly diet control and exercise-based weight loss, for the treatment of dyslipidemia and / or the application of anti-hypoglycemic drugs more than 1 month, was still mixed with hyperlipidemia or Hyperlipidemia combined with more than two risk factors, need to consider the use of fibrates, statins or probucol and other hypolipidemic drugs. This article reviews the use of lipid-lowering drugs in the prevention and treatment of NAFLD.